SLIDE 1
- 2007 Half Year Results
2007 Half Year Results - - PowerPoint PPT Presentation
2007 Half Year Results - - PowerPoint PPT Presentation
2007 Half Year Results
SLIDE 2
SLIDE 3
SLIDE 4
- !" #$%&'# (
)*&$+'+ ,
'*$-$#' ('&) $"'# (+ , Manufacturer of complex molecules,
- f very high added-value,
sold around the world and applying leading-edge technologies
2 fields of activity
SLIDE 5
- *'*&$!* &'.* (!.%-
!"# $%&$'$" $()*# +)*# ,"- " .$'/ #
+' / #'0'# 1, %!.-$ 12, ! *#$ 1, &$!+ 1, .!&"$!'# 1, !" #$%&'# ( )*&$+'+ 32124 '*$-$#' ('&) $"'# (+3214
$&+ ($+0'!+& (0 32214
SLIDE 6
- *$5#$-&'.* ( #('$*&+6-.!&0.('.
SLIDE 7
- '($+&.*$+
- 2 "
- 27 /$00 " 12$ 3$
- 22 $ )* #&'.* !.%- #8%'!$+ 0$45678
- 22 -$$0 '*&/9$ *.&.#'"'$:9#
- 22 $ $1:' %' 678
- 22 $ $0;;' $"$$0 #!.($'* "%%
- 227 -$$0$ '" )#'
$< '" < #
- 222 -$$0 7 #" $0=$
- $$05- *+' <.0'*( *= " $0
- $0=$ $$ 4>? $0$" $0@%
' >?$0 # $ $0"$!'# *#5
- $0
- $ $0;'.+.(%&'.* 1 $A $0/$ 1
$'
SLIDE 8
7
- !$.(='*>
<2, <2, 2<, <,
!$ 7'
- B$1
SLIDE 9
2
- $> ( +&!%#&%!$
+.09%*$
- &9$ *.&.#'"'$
! " , 5- *+' # $" , '*( *= ) %& '" , "$!'# *#
- (#
, .#'?&? ;? !* '+$ =$)*&@+$ )* +,,#- , #$" . $ /" 7, 0# 123 !" #'$$*&! ($ =$! *#$ .!4 #" ! 212, )25613 ;'.+.(%&'.* " 78 , +,253 !.&?%+ 78 1,
SLIDE 10
- !> *'+ &'.*# !&
$*$! ('!$#&.!
- '!" *
($+ !A$&'*>
- .*$5#(%+'B$
%!# +'*> ($+ !A$&'*>
- 5#(%+'B$
($+ !A$&'*> %!.-$ +'$ '(($*$%B$ !$**$+'&$ '" )+'&$ ! ".*+'&$ %!A%+'&$ :C ($+ !A$&'*> ! >! *#$/ ( B.%!+/ .+"$&'#+ ($+ !A$&'*> $D$#*.(.>'$+ ($+ !A$&'*> $!0.!" *#$ #$"'# (+ .%&$!*$ +'&$ ;.%!>.'*/9 (('$% +'&$ .%!$*5+'&$ 9+'&$ :C '*$-$#' ('&) $"'# (+ !" #$%&'# ( )*&$+'+ ="'*'+&! &'.* '* *#$ $+$ !# $B$(.-"$*&
- E% ('&)++%! *#$
$>%( &.!) 00 '!+ , $ $AC:A0
SLIDE 11
)B,. C.B
SLIDE 12
- Strong progression of the EBITDA
and of Current Operating Income
- Strengthening of the Group’s financial structure
Significant events in line with strategy
SLIDE 13
- F$)'>%!$+
)$"$0$
- 3
**56 4*5* C&)B!
- D5
- 5
- !$"$%$
45# D54# $'$
- D5
- 5D
- $'$":
5# 56# 3:$" 5D# 5# 3$0 54 5> $&-!.0'& &&!'G%& G($&.&$!.%- 17 1 )% 65 5> 3" 45 *5 C- 65* D*5 $ !'*> 1 1
EBITDA : + 40.3 % ROC : + 34.8 %
SLIDE 14
- .*+.('= &$= '*#."$ +& &$"$*&
#.*."'# -!$+$*& &'.*
;? (3.6) 5*? (2.9) B: 0.0% 0.0 0.2% (0.2) Others 5D? (6.8) 456? (8.2) !$ " $%$ 0.0% 0.0 1.6% (1.6) " $1$$ 5? 5 D5? D5 C&)B! 1
1 :1C
(17.8) (27.7) (29.4) 89.9
57.0 32.9
<
17 1
(18.6) (27.9) (33.8) 99.3
59.9 39.4
>5?
45? 56#?
D5?
D5>? D5?
%!!$*& .-$! &'*>'*#."$
!" #$%&'# ( )*&$+'+ '*$-$#' ('&) $"'# (+
*54? 45? C: $ 654? 45? 00$ 65? 65? < " '%$# ,
1, 1,
,
1, 21,
$&+ ($+
!" #$%&'# ( )*&$+'+ '*$-$#' ('&) $"'# (+
- !" 0
SLIDE 15
@ 5D# $0E$$0$ :1C / $&!$+%(& .0*.*/#%!!$*& ++$&+ '*&$*=$= &.G$ +.(= 1 17 $&-!.0'& ;# ;# )$ : : 5# 5D# 3 : $" 1 17
- $! &'*>'*#."$
;6# ;# $'$ " : 1 1 %!!$*& .-$! &'*>'*#."$
- !" 0
- .*+.('= &$= '*#."$ +& &$"$*&
SLIDE 16
- .*+.('= &$= G ( *#$+$$&
5 5 0.6 0.6 Other financial assets 1 12 .& ( ++$&+ 1 1 .& (#%!!$*& ++$&+ 65 5> " -% @ 5D 71 *5D 5> 656 6D54 $ % >D5 >>5 )%$ 1 221 .& (*.*/#%!!$*& ++$&+ 5D 4.2 !0" : 45* 45 B'0:" 5> 65 )'0:" 56 56 $$"<
- !" 0
1.0 1.6 Participation in associated companies 1 12 .& ((' G'('&'$+ 1 1 .& (#%!!$*& (' G'('&'$+ 5 >5D 45 >5 $ *54 5 $@ " " $$$0 $'@ " 5> 5 $$$0$%$0$ " ' 1 1 .& (*.*/#%!!$*& (' G'('&'$+ 5* 5 !0" : 5 5 Dynaction loan D54 >D5 .$'@ " D54 5 $%$0$ " ' 21 12 .& ($8%'&) < < '*.!'&) '*&$!$+&+ 169 56: "" 21 12 !$.(=$!6+$8%'&) &&!'G%& G($ &.&$ !.%-
- !" 0
SLIDE 17
- $- )"$*& .0&$ =%$ ".%*& !$> !='*> .%! 0.!"$!+)*='# &$=
(. * 0.!174
- *$D+)*='# &$ (. * 0.!4.B$! )$ !+
- *;'++%$:;.*=+D'& $8%'&) D !! *&+ && #$=C0.! *$& ".%*&
.02143
- 3$ %(D$
- 3 $0&(66666
- 3 $0&(66666
- C: (6!
- )F(>;>?
- (DD$
- &: (D5*$
- &: $"( $ 6!
.*0.!"'*> &.#%!!$*&() $*0.!#$= !%($+<&'+ )G!'=$=$G& '*&$>! &$+ =$G& - !& *= *$8%'&) - !&D'# !'+$ &.1"'(('.*$%!.+ *= "'(('.*$%!.+.*&$ & 9%*$ <!$+-$#&'B$()1
H;
$- )"$*& .07174+)*='# &$ (. *
SLIDE 18
7
- .*+.('= &$= +& &$"$*&+ .0# +0(.D+
:17C :1C $&# +-!.B'=$= G)0'* *#'*> #&'B'&'$+ 161 ;6< 0= ! ">
- 0= ! 0
62
- 0= ! 00 0 !! ?0 "
96; @A9 0= ! ??A?B-? " > 16C 96D 0= ! *? "> 169 16@ 0= ! * 1565 1;6D 0= ! !0=
1 :1C $&# *>$'*# + *= # +$8%'B ($*&+
1 :1C $&# +-!.B'=$= G)'*B$+&'*> #&'B'&'$+ 261 :6C 0= ! !=& ? < 1 $&# +-!.B'=$= G).-$! &'*> #&'B'&'$+
- !" 0
SLIDE 19
,7CB).G3B,C)
SLIDE 20
- .$$ D?#
- 70 6?#
- @ ?#
- #
- .
- $
- =.
- "
- $
- &$'$
+
SLIDE 21
- !A$= $B$*&+
- 1, '$<
- $$ "$ '
- % " $00 $ 70' H#
" $$$#
#&'B'&) -('&
- $@ % @ *?#
- % I?#
- $70' %I*?#;"' $' $ 1
- @$0$/ " %$' %$%' &$$$
'&$+
- 7$% $>0 " <1# " $$" $' ""
$70'
- "$ % C: =$$- $$''"#"
=. %$ "$#
- = % .$$" $ " ' $0
<$"
(*) Custom Manufacturing : made-to-measure synthesis activity of products for the pharmaceutical industry Partnerships : previous site owners
SLIDE 22
- .!$# +&
- . 0%$ "' " $ $
J $@ K%$ "$
- $< L!%$' $0" $/
- '$'
'$$ $' <$ $ ) H# $
- $' <1 ;$ #
- $$0 " $"$ .#
(*) API : Active Pharmaceutical Ingredient
SLIDE 23
)3CC).)BG,C7).
SLIDE 24
- 0$
6?#
- ' %$
$ 6>?#
- 3<$$'
6>?#
- $
- &$'$@+5
- 7$:
- @+
+
SLIDE 25
!A$= B$*&+
- $' '$< (I7,
- "
- $% '
- !%$ $00$ H#
<$
- $$"' 1 $$$0
' $ "@$@ #
- $ $$$ $0
$$'" :
- $!0.!" *#$#$"'# (+
.!$# +&
- $0<$"$
- <' (
- $' "$ "
C C$
- "' $$'$<1
- .'
$%% $" $ 1
(*) Sulfonates : organic molecule containing sulphur whose polarity brings specific performances
SLIDE 26
!A$= B$*&+
- =
$' '$< (I,
- % 0" "
- $
$0'
- $" % "$;
$ + "
- $ $0$" $0$$
" $% $0'
- ! >! *#$/( B.%!+/.+"$&'#+
.!$# +&
- $$0$ " "$
0' $
- 3< $$
<
- $0$F
"' $
- )0$ $0 L! 00$ $ <
$" $'
- $' "%0$
SLIDE 27
!A$= B$*&+
- 1, "
- '$$
$ $0 $" $0$$"00$'( ' "$ " $'$0$%
- " "%$ $0
- $$
"; 0$$<' $' '$< $0 D; ""
- ''$0 "
$' 3$ 1
- )
$' $' $0'$/
- $D&$#*.(.>'$+
.!$# +&
- ) " $ < $
0' $/
- '$$
- C:" ""
$$"4
- $' $0 '$'
"%0$
- "$$0<%""
$ $0 ' """@%; $$%$M#
SLIDE 28
CC,L!C=C.7C3B
SLIDE 29
2
3 $"'*=$!3 +& 00:.0D." B$+C 214'* 7-!.J$#&!$B'$D+:2+&$-+C
$$ IN$@. $LB1##I6
$<$1 $ 7@$L.I)@$#
4$ $$;$0<$
"%$
D$ $<$1$7)*#
- GMP : Good Manufacturing Practices
SLIDE 30
3
$"'*=$!3
2+& 00:.0D." B$+C 14'*
- !.J$#&!$B'$D+:+&$-+C'*$!0.!" *#$$"'# (+ *=
!$B'$D+'**=%+&!' ($"'# (+
3$@7 " " 0$$" $$ .$'/(6$# " $$ 9 (D$# $<$1$$ I&$'$+ ($
- GMP : Good Manufacturing Practices
SLIDE 31
- +&$"$+&$! !.J$#&+
58 32 17 194 55 17 63 42 29 286 85 29
50 100 150 200 250 300 350 400
Projets 2007 Etapes 2007 Projets 2006 Etapes 2006
P erfo rmance chemicals Other fine s peciality chemicals P harmaceutical s ynthes is
2007 project reviews: ‘an increased selectivity’
SLIDE 32
- &! &$>)
&! &$>) 3" J.!=$B$(.-"$*& 5$+1
- Pursuit of “partnership” strategy continues with emerging
structures targeting small quantities: Atlanchim (Borochem & Provence Techno.)
- Seeking high-added value ‘technological niches’:
(‘biomedicines’)
- Development and strengthening of personnel and
analytical tools
SLIDE 33
- ;'.+.(%&'.*
PCAS-Biosolution
9.'*&$*&%!$D'& $ =$!'*G'.&! *+0.!" &'.*+ *=G'.#.*B$!+'.*+
%*'8%$ ((' *#$'*0'*$- !" #$%&'# ( #$"'+&!) 0.! &$ =$B$(.-"$*& .0& !>$& ".($#%($+
.!3 ##$++ &. &.-#( ++&$#*.(.>'# ( -( &0.!" D'# # * !$B.(%&'.*'+$ &$ #( ++'# #$"'# ( +)*&$+'+1
SLIDE 34
;'.+.(%&'.*
- $! &'.*
7( L!(:" $A# 71'(" $A $"$( $/$ ( $ $/ ' 0$ '
'
$ $/;$ $
$%"
< $/ $0OF 71" O/$F
$' $@ $
SLIDE 35
;'.+.(%&'.* '!+& !$+%(&+
- ( ++'# #%+&."$! -!.J$#&+<G%&G'.# & ()+'+ &.G$
'"-!.B$=3
O$F$"$
C:"" ' $0 $$$-1
"0 $ $0
- D*$!+'- -!.J$#&+ .0 $*$!'# KI6&)-$3
$"$(
&$ $% 0$ > $ $0$" &$ 0$ C$$ $0$' $$
:$
Generic ‘+’ : Generics for which an alternative patentable synthesis (and in general more economic) or a formulation process which performs better has been developed
SLIDE 36
CB
SLIDE 37
- GJ$#&'B$+3!.>!$++ .0L 2-( *
$0 (
- (
3<$ " & ! '
)" L$
$"%
3<)B($" " )$ $0J 0' K$ ( $0%;$ " $ "' 4 1 ( @ >78$$ " @ >78$%$
SLIDE 38
7
- GJ$#&'B$+3!.>!$++ .0L 2-( *
' $$'
$A( 0$&$$$5
'' $01< $A $'$'
( " %<
$"'
- ' ' < !$ ($'$' "$
$0!$ " %
SLIDE 39
2
F '+&$= .*%!.('+& #."- !&'"$*&
/#.%!+=$G.%!+$
>; >; D;6 D;>
- /@D
"A@D /@ B$" Increase compared to June 2006: +18,3 % Increase compared to December 2006: + 22,8 % Increase compared to June 06: + 10,2 % Increase compared to December 2006: + 18,7 %
Number of Dynaction shares: 3 295 842 Number of PCAS shares: 13 003 882
)* #&'.*
6;>D ;D D;4 ;*>
- 7
- 7
+D !D + B$"
SLIDE 40
- !A$& (%$
<2 < < < < 2< < < < 7<7 7< 7< < 7<2 7<
- D
4
- D
4
- )
- $
- *
* >
- *
* D
- *
*
- *
* 4
- *
* *
- 6
- >
- D
/
- @
- B
$ "
SLIDE 41
- !A$& (%$
< 7< 7< 7< 2< < 7< < < < < < < 2<
- D
4
- **>
**D ** **4 ***
- 6
- >
D /@ B$"
SLIDE 42
9CB)3
SLIDE 43